Drug Trial News RSS Feed - Drug Trial News

New four-way collaboration aims to improve clinical decision-making in the treatment of colon cancer

New four-way collaboration aims to improve clinical decision-making in the treatment of colon cancer

EKF Diagnostics subsidiary, Selah Genomics, has announced a major, four-way collaboration with Greenville Health System (GHS, South Carolina), DecisionQ Corporation (Virginia), and BD (Becton Dickinson and Company, New Jersey). [More]
Hospira launches first biosimilar monoclonal antibody (mAb) InflectraTM (infliximab) in the UK

Hospira launches first biosimilar monoclonal antibody (mAb) InflectraTM (infliximab) in the UK

Inflectra is licensed for the treatment of inflammatory conditions including rheumatoid arthritis (RA), psoriatic arthritis, ankylosing spondylitis, adult and paediatric Crohn’s disease, adult and paediatric ulcerative colitis and plaque psoriasis. [More]
Sorafenib, sunitinib provide no benefit to patients with locally advanced kidney cancer

Sorafenib, sunitinib provide no benefit to patients with locally advanced kidney cancer

Findings from a federally funded study suggest that patients with locally advanced kidney cancer should not be treated with either adjuvant (post-surgery) sorafenib or sunitinib. The average period to disease recurrence was similar between those who received sorafenib or sunitinib after surgery (5.6 years) and those treated with placebo (5.7 years). [More]
Reslizumab drug appears to reduce risk of severe asthma attacks

Reslizumab drug appears to reduce risk of severe asthma attacks

An investigational drug appears to cut the risk of severe asthma attacks in half for patients who have difficulty controlling the disorder with standard medications, according to results from two multicenter clinical trials. [More]
Actavis files ANDA to market Budesonide Extended-release Tablets

Actavis files ANDA to market Budesonide Extended-release Tablets

Actavis plc today confirmed that it has filed an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration (FDA) seeking approval to market Budesonide Extended-release Tablets, 9 mg. [More]
Isis Pharmaceuticals announces positive results from Phase 1 study of ISIS-PKK Rx for HAE treatment

Isis Pharmaceuticals announces positive results from Phase 1 study of ISIS-PKK Rx for HAE treatment

Isis Pharmaceuticals, Inc. announced today positive results from a Phase 1 study with ISIS-PKKRx. In this study, healthy volunteers treated with ISIS-PKKRx achieved dose-dependent reductions of up to 95 percent in prekallikrein, or PKK. ISIS-PKKRx is a RNA-targeted antisense drug designed to inhibit the production of PKK for the prophylactic treatment of hereditary angioedema (HAE). [More]
Two widely used targeted therapy drugs not effective in preventing return of kidney cancer

Two widely used targeted therapy drugs not effective in preventing return of kidney cancer

Two widely used targeted therapy drugs— approved by the FDA for use in metastatic kidney cancer —are no more effective than a placebo in preventing return of the disease to increase life spans of patients suffering from advanced kidney cancer after surgery, according to new results to be presented by a researcher at the University of Pennsylvania's Abramson Cancer Center during the 2015 Genitourinary Cancers Symposium. [More]
Boehringer Ingelheim presents Phase III data for tiotropium at 2015 AAAAI Annual Meeting

Boehringer Ingelheim presents Phase III data for tiotropium at 2015 AAAAI Annual Meeting

Boehringer Ingelheim today presented data on investigational tiotropium delivered via Respimat inhaler from five Phase III trials from the UniTinA-asthma program at the 2015 American Academy of Allergy, Asthma & Immunology Annual Meeting in Houston, Texas. [More]
Study results report no benefit from use of sunitinib, sorafenib among patients with kidney cancer

Study results report no benefit from use of sunitinib, sorafenib among patients with kidney cancer

Research results highlighted today at the press conference of a major medical meeting report no benefit from the use of either Sutent (sunitinib) or Nexavar (sorafenib) among patients with locally advanced renal cell carcinoma at high risk of recurrence, the ECOG-ACRIN Cancer Research Group announced. [More]
High ThroughputPARP in vivo Pharmacodynamic Assay

High ThroughputPARP in vivo Pharmacodynamic Assay

AMSBIO has introduced a unique High Throughput PARP in vivo Pharmacodynamic Assay that can be used to monitor the efficacy of poly-ADP-ribose polymerase (PARP) inhibitors on PAR formation in vivo; and to measure drug action on PARP in both in vivo and in vitro settings [More]
RepliCel submits CTA for RCS-01 study to treat patients suffering from aged, UV-damaged skin

RepliCel submits CTA for RCS-01 study to treat patients suffering from aged, UV-damaged skin

RepliCel Life Sciences Inc., a clinical stage regenerative medicine company focused on the development of autologous cell therapies, today announced the submission of a Clinical Trial Application (CTA) to the German Competent Authority, the Paul-Ehrlich-Institut (PEI), requesting clearance to initiate a Phase 1 clinical trial investigating the use of RCS-01 to treat patients suffering from aged and UV-damaged skin. [More]

Ferring announces European launch of CORTIMENT®MMX® (budesonide) for ulcerative colitis, and new data re-confirms safety and efficacy

Ferring Pharmaceuticals announced today the European launch of CORTIMENT®MMX® (budesonide), the first and only approved oral controlled release budesonide treatment for active mild-to-moderate ulcerative colitis (UC) where mesalazine (5-ASA) treatment is not sufficient. [More]
Johns Hopkins researcher helps discover effectiveness of three drugs for treating patients with DME

Johns Hopkins researcher helps discover effectiveness of three drugs for treating patients with DME

A researcher from Johns Hopkins Medicine helped lead colleagues from across the country in a government-sponsored study by the Diabetic Retinopathy Clinical Research Network to discover that three drugs -- Eylea, Avastin and Lucentis -- used to treat diabetic macular edema are all effective. They also discovered that Eylea outperformed the other two drugs when vision loss was moderate to severe. [More]
UW ophthalmology researchers help show effectiveness of three drugs for treating DME

UW ophthalmology researchers help show effectiveness of three drugs for treating DME

An ophthalmology research team at the University of Wisconsin-Madison took part in a nationwide clinical trial comparing treatments for a form of diabetic eye disease. The study found that three commonly used drugs perform much the same for those with mild vision problems, but one medication performed better for those with more serious vision loss. [More]
Clinical data demonstrates safety, efficacy of vedolizumab for treatment of adults with UC and CD

Clinical data demonstrates safety, efficacy of vedolizumab for treatment of adults with UC and CD

Takeda Pharmaceuticals International GmbH today announced the presentation of data further demonstrating the efficacy and safety of vedolizumab for the treatment of adults with moderately to severely active ulcerative colitis (UC) and Crohn’s disease (CD). [More]
International phase 2/3 trial shows Gardasil 9 vaccine protects against nine HPV types

International phase 2/3 trial shows Gardasil 9 vaccine protects against nine HPV types

Approximately 12,000 women are diagnosed with cervical cancer each year in the United States and another 4,000 die annually from the disease. However, most cervical cancers are preventable through immunization against the human papillomavirus (HPV). A pivotal international phase 2/3 clinical trial involving Moffitt Cancer Center faculty demonstrated that vaccination with Gardasil 9 protects against nine HPV types, seven of which cause most cases of cervical, vulvar, and vaginal disease. [More]
Palbociclib extends progression-free survival in advanced breast cancer patients

Palbociclib extends progression-free survival in advanced breast cancer patients

Palbociclib, an investigational oral medication that works by blocking molecules responsible for cancer cell growth, is well tolerated and extends progression-free survival (PFS) in newly diagnosed, advanced breast cancer patients, including those whose disease has stopped responding to traditional endocrine treatments. [More]
Palatin introduces clinical trial website in support of bremelanotide phase 3 study for FSD treatment

Palatin introduces clinical trial website in support of bremelanotide phase 3 study for FSD treatment

Palatin Technologies, Inc., a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical needs and commercial potential, today announced that it has launched a clinical trial website in support of its phase 3 reconnect study with bremelanotide for the treatment of female sexual dysfunction (FSD). [More]
Eli Lilly accepts committee recommendation to extend evacetrapib Phase 3 trial

Eli Lilly accepts committee recommendation to extend evacetrapib Phase 3 trial

Eli Lilly and Company has accepted the recommendation of the ACCELERATE study academic executive committee, based on emerging science in the cardiovascular field, to extend the Phase 3 trial of the investigational medicine evacetrapib by approximately six months. [More]
Researchers demonstrate clinical efficacy of gallopamil in severe asthma patients

Researchers demonstrate clinical efficacy of gallopamil in severe asthma patients

A team of Inserm researchers from the Cardio-Thoracic Research Centre of Bordeaux (Inserm/University of Bordeaux and Bordeaux University Hospital) has demonstrated the clinical efficacy of gallopamil in 31 patients with severe asthma. This chronic disease is characterised by remodelling of the bronchi, which exacerbates the obstruction of the airways already seen in "classic" asthma. [More]